Premalignant and malignant skin tumours in immunosuppressed patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000009:adverse effects; D002102:Cadaver; D002280:Basal Cell Carcinoma / Q000453:epidemiology* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000276:immunology; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007636:Keratoacanthoma / Q000453:epidemiology* / Q000276:immunology; D007642:Keratosis / Q000453:epidemiology* / Q000276:immunology; D016030:Kidney Transplantation; D008048:Lip Neoplasms / Q000453:epidemiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000453:epidemiology* / Q000276:immunology; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000276:immunology; D013997:Time Factors; D014019:Tissue Donors
D003520:Cyclophosphamide; D001379:Azathioprine